Qiagen N.V. (QGEN) has successfully navigated the second quarter of 2026, delivering financial results that not only met but exceeded its own sales and profitability projections. The company remains confident in its full-year guidance, forecasting a significant acceleration in sales growth during the latter half of the year. This optimistic outlook is fueled by several key factors: the resolution of challenges posed by previously discontinued product lines, the successful launch of innovative new automation systems, and a strategic expansion of its diagnostic offerings. Additionally, Qiagen's leadership is actively engaged in a continuous strategic review to maximize shareholder value while simultaneously searching for a new Chief Executive Officer.
During the second quarter of 2026, Qiagen reported net sales of $535 million, demonstrating stability year-over-year on a reported basis and outperforming the company's projection of a 2% decline at constant exchange rates. Adjusted diluted earnings per share reached $0.62, exceeding the initial forecast of at least $0.60 at constant exchange rates. These robust figures highlight the company's resilience and reinforce confidence in its annual outlook. Growth was particularly strong in key areas: Sample Technologies saw a 9% increase at constant exchange rates, driven by demand for automated consumables and instruments. QIAcuity experienced double-digit growth at constant exchange rates, largely due to strong demand for digital PCR consumables. QuantiFERON sales rebounded with a 1% growth at constant exchange rates, overcoming a significant drop in U.S. immigration testing demand, which had been noted in the previous quarter.
However, the diagnostic solutions segment saw a 2% decline at constant exchange rates. QIAstat-Dx sales specifically fell by 7% at constant exchange rates, primarily due to a challenging comparison with the prior year's strong respiratory testing numbers, despite growth in gastrointestinal and meningitis/encephalitis panels. In PCR and nucleic acid amplification, sales decreased by 8% at constant exchange rates, with strong QIAcuity performance offset by weaker OEM demand. The genomics and NGS product group achieved a 2% increase at constant exchange rates, boosted by solid single-digit growth from Qiagen Digital Insights and over 20% growth in universal NGS panel consumables for third-party sequencers. This growth was somewhat tempered by lower sales of other genomics products. Geographically, performance varied: the Americas grew by 1% at constant exchange rates, led by North America, while EMEA declined by 2% due to mixed regional results, and Asia Pacific also saw a 2% decline, primarily impacted by a decrease in China, though China's sequential sales improved significantly.
Qiagen maintained a high level of profitability, with adjusted operating income reaching $157 million, a 2% decrease from the second quarter of 2025. The adjusted operating income margin stood at 29.4%, a slight dip from 29.9% in the previous year, attributed to shifts in product mix. Despite these changes, disciplined cost management and efficiency gains helped mitigate gross margin headwinds. The adjusted gross margin was 66.2%, compared to 66.7% in the prior-year quarter. Operating expenses remained stable as a percentage of sales. The company also generated robust operating cash flow of $301 million for the first half of 2026, consistent with the previous year, despite investments in efficiency programs and increased inventory for upcoming product launches. This financial strength allowed for a 40% increase in the annual dividend to $0.35 per share and the completion of a $500 million synthetic share repurchase in January.
Looking ahead, Qiagen has reaffirmed its full-year sales growth guidance of approximately 1% to 2% at constant exchange rates and adjusted diluted EPS of at least $2.43 at constant exchange rates. For the third quarter, sales growth is expected to be between 1% and 2% at constant exchange rates, with adjusted diluted EPS of at least $0.62. The company anticipates a sequential improvement in sales growth in the second half of the year, driven by the cessation of impacts from discontinued product lines, increased contributions from new Sample Technologies systems and other product launches, and the strong performance of Parse, which is exceeding its 2026 sales target. New product developments, such as the U.S. FDA clearance for QIAstat-Dx Bloodstream Infection Identification panels and a fully automated Sample to Insight workflow for QuantiFERON testing, along with collaborations with NVIDIA for drug discovery, are expected to further bolster future growth.
The company's strategic vision involves a continuous assessment of its portfolio and market opportunities to ensure sustainable growth and value creation. The ongoing Chief Executive Officer search and strategic review are seen as complementary processes designed to enhance stakeholder value. Thierry Bernard emphasized that while funding conditions in the U.S. research and academic sectors are improving sequentially, caution is still warranted as overall NIH outlay remains below the previous year. This balanced approach to innovation, operational efficiency, and market strategy positions Qiagen for continued success in the competitive life sciences industry, focusing on areas with high growth potential and unmet clinical needs, such as complicated UTI panels and advanced single-cell analysis solutions.
In conclusion, Qiagen has demonstrated impressive performance in the second quarter of 2026, exceeding financial targets and maintaining strong profitability. The company's strategic focus on innovation, particularly in Sample Technologies, digital PCR, and diagnostic solutions, is driving growth and setting the stage for a stronger second half of the year. With new product launches, expanded applications, and strategic partnerships, Qiagen is well-positioned to capitalize on market opportunities and deliver sustained value to its shareholders, reinforcing its commitment to leadership in the life sciences sector.
